Final results of the huge ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial suggest that anastrozole (Arimidex, AstraZeneca) is the initial treatment of choice for postmeno-pausal women with hormone receptor positive early breast cancer. The trial, which showed both better efficacy and a far superior side effect profile for anastrozole versus tamoxifen, enrolled 9,366 patients recruited from 381 centers in 21 countries.
Go to Previous Page
Go to Next Page